Prostatitis is associated with inflammation (and or neural upregulation or sensitization), and in a few cases, infection of the prostate, causing pain in the prostate and pelvic area along with variable urinary symptoms. Acute bacterial prostatitis is rare, quite severe, relatively simple to diagnose, and quite easy to cure with...
Viewing entries tagged
At the first ever Active Surveillance Convention, a conference I attended back in 2007, many experts openly bemoaned that the word “CANCER” profoundly overstates the significance of Gleason 6 type of prostate cancer. The pathologists at the conference, however, shot down the idea of a name change saying, “Under the microscope it looks like a cancer, so it is cancer.” No one at the conference had a rebuttal so the proposal for a name change was dropped.
Proton beam therapy, a form of external beam radiation, has been around for a while but is less commonly utilized than other forms of radiation therapy, which is partly due to availability. Certain properties of protons show potential for a different approach to radiation therapy. This article also considers how implementation of imaging helps improve treatment outcomes.
PCRI's free Helpline connects patients and caregivers with educational advocates and helps them understand their personal case. This article is a top ten frequently asked questions list that our Helpline receives.
Prostate size is an additional factor besides Gleason score, PSA, and the percentage of core biopsies involved with cancer, that needs to be considered when going through the treatment selection process.
Radium-223 Dichloride, otherwise known as Xofigo, is the first alpha-emitting radiopharmaceutical used to treat prostate-cancer-related bone metastasis. The FDA approved Xofigo in May of 2013. The clinical trial that led to the FDA approval was called the ALSYMPCA trial. Eligible patients were randomized in a 2:1 fashion to either receive six monthly intravenous injections of radium-223 or best standard of care, such as antiandrogen hormonal therapy, local external beam radiation, corticosteroids, estramustine, or ketoconazole. The men who received radium-223 had improvement in bone pain and also experienced an increased survival.
A new oral medication called ARAMIS is being evaluated in men who have rising PSA levels on Lupron and whose bone scans remain clear. For more information, visit: https://clinicaltrials.gov/show/NCT02200614
The Cheapest, Best, Safest Available “Drug” for Cancer-Related Fatigue (CRF) that no one knows about until now, despite being proven to work at the Mayo Clinic, MD Anderson Cancer Center & 40+ other medical centers many years ago!!??? What the heck is Moyad talking about?! (Shameless plug #235-See “The Supplement Handbook” by Moyad on Amazon after reading this article).
Ken Griffey Sr. is a three-time baseball all-star, a prostate cancer survivor, and a spokesperson for Bayer’s Men Who Speak Up program, which encourages men with advanced prostate cancer to know the symptoms of progressing disease and offers resources to help them feel more comfortable speaking up about it. Mr. Griffey, who is conducting a nationwide Men Who Speak Up tour with his son, Hall-of-Famer Ken Griffey Jr., will be a guest speaker at the 2016 Prostate Cancer Conference on September 10.
Sunnybrook Health Sciences Centre’s Laurence Klotz, MD, speaks with PCRI about management of low-risk prostate cancer with Active Surveillance.
What is active surveillance, and how does it compare with other methods of treating prostate cancer?
The concept of conservative management for prostate cancer is not new. In fact, in Scandinavia and England in the 70s, basically no one was treated until they had metastatic disease. And the idea was that treatment....